Table 2.

Trial Infusions.^*

Variable	Levothyroxine Group (N = 419)	Saline Group (N = 419)
Assigned infusion started — no. (%)†	411 (98)	384 (92)
Levothyroxine weaned before 12 hr — no./total no. (%)	47/411 (11)‡	NA
Levothyroxine discontinued before 12 hr — no./total no. (%)	58/411 (14)‡	NA
≥6 Hr of exposure to levothyroxine or saline — no. (%)§	351 (84)	374 (89)
Median dose of levothyroxine given within 12 hr (IQR) — μg	360 (360–360)	0 (0–0)
Echocardiography performed — no. (%)	350 (84)	336 (80)
Net fluid balance over period of 12 hr — ml	1181±1563	938±1707
Median time from infusion of levothyroxine or saline to organ recovery (IQR) — hr	42 (25–59)	44 (24–58)
Open-label levothyroxine
Given beyond 12 hr — no./total no. (%)	209/411 (50)	50/395 (12)
Median dose given beyond 12 hr — μg¶	527 (190–932)	522 (253–966)
Median cumulative dose of levothyroxine for all donors — μg	360 (360–868)	0 (0–0)
Median free T4 level at time of organ recovery — ng/dl	1.4 (1.1–2.1)	1.0 (0.7–1.3)

^*Plus–minus values are means ±SD. Unless otherwise indicated, the numbers of donors with missing data were as follows: net fluid balance, 33 in the levothyroxine group and 46 in the saline group; time from infusion to organ recovery, 16 and 42; cumulative dose of T4, 13 and 24; and free T4 level at time of organ recovery, 115 and 131. NA denotes not applicable.

^†Of the donors in whom the levothyroxine infusion was started, 33 had a starting dose other than 30 μg per hour. Of the donors in whom the saline infusion was started, 23 received the infusion at a rate other than 30 ml per hour. Reasons that the assigned infusion was not started are provided in Table S5.

^‡A total of 86 had the levothyroxine infusion weaned or discontinued (or both).

^§The per-protocol population comprised the donors who received at least 6 hours of their assigned infusion.

^¶The dose given beyond 12 hours represents the median only in donors who received open-label levothyroxine.